To test an additional model of B-cell malignancy, we used Abelson-driven pro-B-cell tumors43 (a model of B-cell acute lymphoblastic leukemia) in the same settings of anti-CD19 CAR4 T-cell therapy in vivo (Fig. 1a and Extended Data Fig. 1a). Here, CD19 is linked to B-cell acute lymphoblastic leukemia.